NRX Pharmaceuticals
NRXP
30 hedge funds and large institutions have $1.86M invested in NRX Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 8 closing their positions.
93% more capital invested
Capital invested by funds: $965K → $1.86M (+$893K)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.03% more ownership
Funds ownership: 0.45% → 0.47% (+0.03%)
12% less funds holding
Funds holding: 34 → 30 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$212K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$15.1K |
| 3 |
Morgan Stanley
New York
|
+$13.7K |
| 4 |
Renaissance Technologies
New York
|
+$12.1K |
| 5 |
JP Morgan Chase
New York
|
+$5.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$84.5K |
| 2 |
Millennium Management
New York
|
-$40.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$13.8K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$12.6K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.67K |
NRXP Hedge Fund Activity: Q4 2023 in Review
30 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2023, worth a combined $1.86M — up 93% from $965K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NRXP and 4 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $212K. The largest seller was Sabby Management, exiting entirely with an estimated $84.5K sold.
- 30 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2023, down from 34 in Q3 2023.
- Funds reported $1.86M of NRX Pharmaceuticals stock for Q4 2023, up 93% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q4 2023 and 8 closed out, a net change of -4 holders.
- The largest NRX Pharmaceuticals buyer in Q4 2023 was AdvisorShares Investments, an estimated $212K added.
- The largest NRX Pharmaceuticals seller in Q4 2023 was Sabby Management, an estimated $84.5K sold.
Based on aggregated 13F filings for Q4 2023.